In brief: Living Cell Technologies, Phosphagenics, Rockeby, Antisense, Prima, Proteome Systems
Friday, 14 October, 2005
Living Cell Technologies (ASX:LCT) has appointed US based neuroscientist Dr Dwaine F Emerich as chief scientific officer of LCT BioPharma. He has been LCT's US vice-president of research since 2003, joining the company from Sertoli Technologies.
Phosphagenics' (ASX:POH) has appointed Dr Esra Ogru, vice-president of research & development, to the board of directors.
Rockeby biomed (ASX:RBY) has signed a five-year exclusive agreement with Pharmaplan South Africa for the marketing and distribution of CanDia5, its point-of-care test kit to detect Vulvo-Vaginal Candidiasis, in South Africa. The sales of CanDia5 through Pharmaplan are expected to generate revenue for Rockeby in the current financial year.
Antisense Therapeutics' (ASX:ANP) development director Dr Jega Iswaran has resigned. The company's clinical development program will now be overseen by development manager, Nuket Desem.
Prima Biomed (ASX:PRR) has completed inital recruitment of its phase IIa clinical trial in ovarian cancer at the Austin Hospital in Melbourne.
Proteome Systems (ASX:PXL) has signed a heads of agreement with Prince Henry's Institute Medical Research (PHIMR) to combine their IP to develop an ovarian cancer diagnostic test.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
